focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2020 16:00

RNS Number : 3749L
AstraZeneca PLC
29 April 2020
 

29 April 2020 16:00 BST

 

Results of Annual General Meeting held on 29 April 2020

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2019

 

1,061,180,101

99.92

872,215

0.08

1,062,052,316

80.93%

7,121,452

2

To confirm dividends

 

1,058,995,786

99.10

9,598,531

0.90

1,068,594,317

81.43%

579,469

3

To reappoint PricewaterhouseCoopers LLP as Auditor

 

1,068,300,235

99.97

312,449

0.03

1,068,612,684

81.43%

560,776

4

To authorise the Directors to agree the remuneration of the Auditor

 

1,067,398,628

99.90

1,086,858

0.10

1,068,485,486

81.42%

687,961

5a

To re-elect Leif Johansson as a Director

 

1,065,113,167

99.69

3,276,071

0.31

1,068,389,238

81.42%

784,805

5b

To re-elect Pascal Soriot as a Director

 

1,067,248,723

99.90

1,033,124

0.10

1,068,281,847

81.41%

892,364

5c

To re-elect Marc Dunoyer as a Director

 

1,060,164,242

99.25

8,056,265

0.75

1,068,220,507

81.40%

952,979

5d

To re-elect Geneviève Berger as a Director

 

882,846,920

83.06

179,994,848

16.94

1,062,841,768

80.99%

6,331,650

5e

To re-elect Philip Broadley as a Director

 

1,066,048,992

99.79

2,190,705

0.21

1,068,239,697

81.41%

933,713

5f

To re-elect Graham Chipchase as a Director

 

1,062,682,507

99.48

5,520,936

0.52

1,068,203,443

81.40%

969,967

5g

To elect Michel Demaré as a Director

 

1,066,252,259

99.82

1,969,593

0.18

1,068,221,852

81.40%

951,558

5h

To re-elect Deborah DiSanzo as a Director

 

1,067,836,362

99.97

351,091

0.03

1,068,187,453

81.40%

985,957

5i

To re-elect Sheri McCoy as a Director

 

1,064,329,862

99.64

3,890,368

0.36

1,068,220,230

81.40%

951,792

5j

To re-elect Tony Mok as a Director

1,067,117,370

99.90

1,066,669

0.10

1,068,184,039

81.40%

989,371

5k

To re-elect Nazneen Rahman as a Director

 

1,067,376,963

99.92

821,467

0.08

1,068,198,430

81.40%

973,592

5l

To re-elect Marcus Wallenberg as a Director

 

955,082,665

89.42

113,060,725

10.58

1,068,143,390

81.40%

1,030,019

6

To approve the Annual Report on Remuneration for the year ended 31 December 2019

 

1,032,308,145

96.65

35,747,783

3.35

1,068,055,928

81.39%

1,118,038

7

To approve the Directors' Remuneration Policy

 

972,774,742

94.71

54,292,376

5.29

1,027,067,118

78.27%

42,106,679

8

To authorise limited political donations

 

1,038,907,152

97.75

23,872,400

2.25

1,062,779,552

80.99%

6,394,668

9

To authorise the Directors to allot shares

 

910,654,650

85.26

157,472,093

14.74

1,068,126,743

81.40%

1,046,979

10

To authorise the Directors to disapply pre-emption rights

 

1,058,066,972

99.23

8,200,338

0.77

1,066,267,310

81.26%

2,906,339

11

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

 

1,054,711,677

98.92

11,513,414

1.08

1,066,225,091

81.25%

2,948,557

12

To authorise the Company to purchase its own shares

 

1,051,131,060

98.41

16,950,800

1.59

1,068,081,860

81.39%

1,091,896

13

To reduce the notice period for general meetings

 

998,062,805

93.44

70,101,553

6.56

1,068,164,358

81.40%

1,008,865

14

To approve the 2020 Performance Share Plan

1,010,149,491

95.66

45,877,396

4.34

1,056,026,887

80.48%

13,147,356

 

Issued capital

As at 27 April 2020, the number of issued shares of the Company was 1,312,240,429 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGPPURCCUPUGCB
Date   Source Headline
29th Sep 20217:00 amRNSAstraZeneca to fully acquire Caelum Biosciences
28th Sep 20217:00 amRNSSaphnelo approved in Japan for SLE
24th Sep 20217:00 amRNSLynparza PROpel trial meets primary endpoint
23rd Sep 20217:00 amRNSBoard Committee Change
23rd Sep 20217:00 amRNSNew Sustainability Committee of the Board
21st Sep 20217:00 amRNSAstraZeneca $360m Irish manufacturing investment
20th Sep 20217:00 amRNSEnhertu reduced risk of disease progression by 72%
9th Sep 20214:00 pmRNSImfinzi improves survival in NSCLC in POSEIDON
9th Sep 20217:00 amRNSPT027 PhIII asthma trials met primary endpoints
3rd Sep 20217:00 amRNSUltomiris approved in EU for children with PNH
1st Sep 20213:00 pmRNSTotal Voting Rights
26th Aug 20217:05 amRNSForxiga approved in Japan for CKD
26th Aug 20217:00 amRNSALXN1840 Wilson Phase III met primary endpoint
20th Aug 20217:05 amRNSUpdate on Ultomiris Phase III ALS trial
20th Aug 20217:00 amRNSAZD7442 prophylaxis trial met primary endpoint
16th Aug 20213:00 pmRNSDirector/PDMR Shareholding
11th Aug 20212:35 pmRNSUpdate on US review of roxadustat
9th Aug 20217:05 amRNSForxiga approved in the EU for CKD
9th Aug 20217:00 amRNSEnhertu head-to-head trial meets primary endpoint
2nd Aug 20213:00 pmRNSTotal Voting Rights
2nd Aug 20217:00 amRNSSaphnelo approved in the US for SLE
29th Jul 20217:00 amRNSAZN: H1 2021 Results
26th Jul 20217:00 amRNSUltomiris recommended in EU for children with PNH
22nd Jul 20217:00 amRNSDirectorate Change
21st Jul 20213:56 pmRNSDirector/PDMR Shareholding
21st Jul 20213:45 pmRNSTotal Voting Rights
21st Jul 20211:45 pmRNSAcquisition of Alexion completed
19th Jul 20217:00 amRNSImfinzi approved in China for extensive-stage SCLC
16th Jul 20217:00 amRNSStatus on US FDA Advisory Committee for roxadustat
15th Jul 20215:30 pmRNSAstraZeneca
14th Jul 20217:08 amRNSAstraZeneca-Alexion transaction cleared in the UK
8th Jul 20217:00 amRNSTezepelumab granted FDA Priority Review for asthma
6th Jul 20217:00 amRNSAstraZeneca-Alexion transaction cleared in the EU
1st Jul 20213:00 pmRNSTotal Voting Rights
28th Jun 20217:05 amRNSForxiga recommended in EU for patients with CKD
28th Jun 20217:00 amRNSNirsevimab PhII/III trial confirms safety profile
24th Jun 20217:00 amRNSLynparza approved in China for prostate cancer
23rd Jun 20217:00 amRNSOrpathys approved in China for lung cancer
22nd Jun 20217:00 amRNSKoselugo approved in the EU for children with NF1
15th Jun 20217:00 amRNSUpdate on AZD7442 STORM CHASER trial
10th Jun 202111:32 amRNSStabilisation Notice
7th Jun 20217:00 amRNSCalquence head-to-head results versus ibrutinib
4th Jun 20217:05 amRNSLynparza reduced recurrence risk in breast cancer
4th Jun 20217:00 amRNSAstraZeneca appoints new Chief Financial Officer
2nd Jun 20217:00 amRNSPublication of Final Terms
1st Jun 20213:01 pmRNSBlock listing Interim Review
1st Jun 20213:00 pmRNSTotal Voting Rights
28th May 20217:00 amRNSTagrisso approved in EU in early lung cancer
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.